Trial Results Show Significant Blood Sugar Reduction
Novo Nordisk said its phase 3a PIONEER TEENS trial demonstrated a statistically significant reduction in blood sugar levels, with HbA1c declining by 0.83% compared to placebo at 26 weeks.
The study evaluated oral semaglutide in 132 children and adolescents aged 10-17 and showed a safety profile consistent with previous semaglutide trials.
“This confirms that oral semaglutide is an effective treatment option for children and adolescents with type 2 diabetes,” said Martin Holst Lange, chief scientific officer at Novo Nordisk.
The company said the trial represents the first clinical study of an oral GLP-1 receptor agonist therapy in this age group, addressing a significant unmet need.
Novo Nordisk expects to file for regulatory approval to expand the label for oral semaglutide in the U.S. and EU in the second half of the year.
Novo Nordisk Shares Edge Higher
NVO Price Action: At the time of publication, Novo Nordisk shares are trading 3.66% higher at $39.93, according to data from Benzinga Pro.
Image via Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.